Pre-made Itolizumab benchmark antibody ( Whole mAb, anti-CD6/TP120 therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-284

Pre-Made Itolizumab biosimilar, Whole Mab: Anti-CD6/TP120 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Itolizumab (INN, trade name Alzumab) is a "first in class" humanized IgG1 monoclonal antibody developed by Biocon and the Center of Molecular Immunology (CIM), Havana.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-284-1mg 1mg 3090 Inquiry Inquiry

Size: 1mg | 10mg | 100mg


Products Name (INN Index) Pre-Made Itolizumab biosimilar, Whole Mab: Anti-CD6/TP120 therapeutic antibody
INN Name Itolizumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2010
Year Recommended2011
CompaniesCenter of Molecular Immunology;Biocon;Biotech Pharmaceutical;Equillium
Conditions ApprovedPlaque psoriasis
Conditions ActiveGraft-versus-host disease;Cytokine release syndrome;COVID-19;Asthma;Lupus nephritis
Conditions DiscontinuedAutoimmune disorders;Multiple sclerosis;Psoriasis;Rheumatoid arthritis
Development Techna